TEM

TEM

USD

Tempus AI Inc. Class A Common Stock

$52.900-0.250 (-0.470%)

Цена в режиме реального времени

Healthcare
Health Information Services
Соединенные Штаты

График цен

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$53.150

Максимум

$54.550

Минимум

$52.220

Объем

0.42M

Фундаментальные показатели компании

Рыночная капитализация

9.3B

Отрасль

Health Information Services

Страна

United States

Статистические данные торговли

Средний объем

13.59M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $22.89Текущая $52.900Максимум $91.45

Отчет об анализе ИИ

Последнее обновление: 25 апр. 2025 г.
Сгенерировано ИИИсточник данных: Yahoo Finance, Bloomberg, SEC

TEM: Tempus AI Inc. Class A Common Stock - Analyzing Recent Buzz and What the Data Suggests

Stock Symbol: TEM Generate Date: 2025-04-25 23:24:22

Alright, let's break down what's been happening with Tempus AI, ticker symbol TEM. This company is all about using AI to make healthcare, especially precision medicine and cancer care, smarter. They work with doctors, drug companies, and researchers, basically trying to make sense of complex health data.

What's the Latest News Buzz?

Looking at the recent headlines, the vibe around Tempus AI seems pretty upbeat. There's a lot of positive stuff popping up.

For starters, they're presenting a bunch of research – 18 different abstracts, including one big oral presentation – at a major cancer research meeting soon. That's a good sign; it shows they're active in the scientific community and have findings to share.

Analysts are also chiming in with positive views. Both Needham and BTIG recently put out "Buy" ratings on the stock. Needham even reiterated their $70 price target, while BTIG set theirs at $60. Getting endorsements from Wall Street analysts usually helps boost confidence.

Beyond that, Tempus announced they're launching a new advisory board packed with leading doctors. Bringing in top medical minds can definitely strengthen their strategy and credibility. Plus, they just inked a partnership with Illumina, a big name in genomics, to work on AI for precision medicine. Collaborations like this are a big deal in the biotech and healthcare tech world.

And zooming out a bit, the news about the global AI diagnostics market expected to grow significantly is also a positive backdrop for a company like Tempus. It suggests they're operating in a growing space.

The only piece of news that's more of a heads-up than a sentiment driver is the announcement of their first-quarter earnings report date (May 6th). That's an important event to watch, but the news itself is neutral.

So, overall, the news flow is heavily tilted towards the positive side, highlighting company progress, strategic moves, and analyst optimism.

Checking the Stock's Recent Moves

Now, let's look at what the stock price has actually been doing. If you glance at the chart over the last month or so, it's been quite a ride.

The price took a noticeable dip through late March and early April, falling from the low $50s down into the high $30s. That was a pretty sharp drop.

But then, things changed quickly. Starting around April 21st, the stock saw a strong rebound. It jumped back up from the low $40s and is now trading around the low $50s again. The previous day's close was $53.50, and today it's hovering right around there. This recent bounce has been accompanied by higher trading volume, which often suggests stronger buying interest.

Comparing the current price to its 52-week range ($22.89 to $91.45), it's sitting roughly in the middle, but still a good distance below its peak from earlier in the year.

What about the very near future? The AI prediction model suggests the stock might continue this upward trend, forecasting modest gains of around 1.4% today, 2.0% tomorrow, and 2.3% the day after.

Putting It Together: What Might Be Next?

Considering the wave of positive news, the recent strong rebound in the stock price, and the AI's short-term forecast for continued upward movement, the current situation seems to lean towards favoring potential buyers or those already holding the stock. There's a clear sense of positive momentum right now.

Potential Strategy Ideas (Thinking Out Loud):

Given the recent run-up, the stock might have gotten a bit ahead of itself in the very short term (some technical indicators suggest it's "overbought"). However, the overall picture from the news and analyst targets is quite positive.

  • Potential Entry Consideration: If you're looking at getting in, the data points to potential entry areas right around the current price, maybe slightly below $54. The recent price action shows this area is where the stock is currently trading after its bounce.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always key. A potential stop-loss level to consider could be around $48.16. Why there? It's below the recent low point of the sharp rebound, so if the stock falls back below that level, it might signal the bounce is over. For taking profits, a potential level to watch in the medium term could be around $59.12, which aligns with one of the recommended targets based on the data. Keep in mind analysts have higher targets ($60, $70), and the AI even projects a potential $81.16 longer-term, suggesting there could be more room to run if the positive trends continue.

A Little More Context

Remember, Tempus AI is a healthcare technology company heavily invested in AI. This means their success is tied to innovation, partnerships (like the one with Illumina), and getting their technology adopted in the medical field. The news about research presentations and the advisory board fits right into this.

It's also important to know they are currently a growth company, meaning they are investing heavily and aren't profitable yet (that negative P/E ratio tells you that). This is common in this stage but also means the stock can be more volatile. The high debt level is another factor to keep in mind as a potential risk.

Overall, the recent story for TEM is one of strong positive news driving a significant price rebound, with analysts and AI predictions suggesting more potential upside, though risks like high debt and short-term overbought conditions exist.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Связанные новости

BusinessWire

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for

Просмотреть больше
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
BusinessWire

Tempus to Report First Quarter 2025 Financial Results on May 6

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold

Просмотреть больше
Tempus to Report First Quarter 2025 Financial Results on May 6
Analyst Upgrades

Needham Reiterates Buy on Tempus AI, Maintains $70 Price Target

Needham analyst Ryan MacDonald reiterates Tempus AI with a Buy and maintains $70 price target.

Просмотреть больше
Needham Reiterates Buy on Tempus AI, Maintains $70 Price Target
Analyst Upgrades

BTIG Initiates Coverage On Tempus AI with Buy Rating, Announces Price Target of $60

BTIG analyst Mark Massaro initiates coverage on Tempus AI with a Buy rating and announces Price Target of $60.

Просмотреть больше
BTIG Initiates Coverage On Tempus AI with Buy Rating, Announces Price Target of $60
BusinessWire

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital

Просмотреть больше
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
GlobeNewswire

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

PALM BEACH, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today's AI-driven world, the use of

PR Newswire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and...

Прогноз ИИBeta

Рекомендация ИИ

Бычий

Обновлено в: 28 апр. 2025 г., 06:07

МедвежийНейтральныйБычий

67.6% Уверенность

Риск и торговля

Уровень риска3/5
Средний риск
Подходит для
СтоимостьРост
Руководство по торговле

Точка входа

$52.99

Взять прибыль

$58.16

Остановить убытки

$47.61

Ключевые факторы

DMI показывает медвежий тренд (ADX:10.7, +DI:12.0, -DI:13.5), что предполагает осторожность
Текущая цена очень близка к уровню поддержки ($52.88), что предполагает сильную возможность покупки
Объем торгов в 1.8 раз превышает среднее значение (122,674), что указывает на повышенное участие рынка
MACD -0.0895 выше сигнальной линии -0.0917, что указывает на бычье пересечение

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.